[1] Kim N.Chemoprevention of gastric cancer by Helicobacter pylori eradication and its underlying mechanism[J].J Gastroenterol Hepatol,2019,34(8):1287-1295.
[2] Mccoll KE.Clinical practice.Helicobacter pylori infection[J].N Engl J Med,2010,362:1597-1604.
[3] 薛建华,俞海萍,单雪晴.上海地区职业人群幽门螺杆菌感染现状及其影响因素[J].环境与职业医学,2021,38(3):272-277.
[4] 吕农华,谢川.我国幽门螺杆菌感染研究的回顾与展望[J].中华消化杂志,2021,41(4):217-220.
[5] 叶珊珊,李俊达,周应生,等. 幽门螺杆菌对抗生素耐药性的多中心前瞻性分析[J]. 基础医学与临床,2020,40(12):1661-1665.
[6] Song Z, Zhang J, He I, et al.Prospective multi-region study on primary antibiotic resistance of Helicobacter pylori strains isolated from Chinese patients[J].Dig Liver Dis,2014,46:1077-1081.
[7] 国家消化系疾病临床医学研究中心(上海),国家消化道早癌防治中心联盟,中华医学会消化病学分会幽门螺杆菌和消化性溃疡学组,等.中国居民家庭幽门螺杆菌感染的防控和管理专家共识(2021年)[J].中华消化杂志,2021,41(4):221-233.
[8] 国家消化系统疾病临床医学研究中心(上海)国家消化道早癌防治中心联盟,中华医学会消化病学分会幽门螺杆菌学组,中华医学会外科学分会胃癌学组,等.中国幽门螺杆菌根除与胃癌防控的专家共识意见(2019年,上海)[J].中华健康管理学杂志,2019,13(4):285-291.
[9] 年媛媛,张红杨,孟宪梅.结节性胃炎患者难治性幽门螺杆菌感染的耐药分析和治疗[J].胃肠病学,2021,26(1):35-38.
[10] Nishikawa I, Kato J, Terasoma S, et al.Nodular gastritis in association with gastric cancer development before and after Helicobacter pylori eradication[J]. JGH Open, 2018, 2(3): 80-86.
[11] Otsuka T, Sugimoto M, Inoue R, et al.Influence of potassiumcompetitive acid blocker on the gut microbiome of Helicobacter pylori-negative healthy individuals[J]. Gut,2017,66(9):1723-1725.
[12] 牛占岳, 宋志强, 周丽雅. 中国大陆地区成人幽门螺杆菌耐药情况及变迁[J]. 中华内科杂志, 2016, 55(9): 734-736.
[13] Mailfertheiner P, Megraud F, O’morain CA, et al.Management of Helicobacter pylori infection the Maastricht IV/Florence Consensus Report[J].Gut,2012,61:646-664.
[14] Zhou L, Zhang J, Chen M, et al.A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection:a randomized multicenter trial[J].Am J Gastroenterol, 2014, 109:535-541.
[15] Wei Z, Chen Q, Liang X, et al.Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy[J]. Gut, 2015, 64(11):1715-1720.
[16] Rimbara E, Fischbach LA, Graham DY .Optimal therapy for Helicobacter pylori infections[J]. Nat Rev Gastroenterol Hepatol, 2011, 8(2):79-88.
[17] 中华医学会消化病学分会幽门螺杆菌学组/全国幽门螺杆菌研究协作组,刘文忠,谢勇,等. 第四次全国幽门螺杆菌感染处理共识报告[J]. 中华消化杂志,2012,32(10):655-661. |
